Regulora is a PDT that is accessed through a smartphone app. It consists of seven therapy sessions provided over three months, with practice sessions between. Regulora is delivers Gut-Directed Hypnotherapy (GDH) and includes the collection of adherence data and patient reported outcomes using clinically-validated survey instruments. Unlike most digital therapeutics that focus on behavioral health issues, Regulora treats abdominal pain, a somatic symptom that is the chief IBS complaint. For decades, in-person psychological interventions have been effective in treating IBS but were accessible to very few patients.

Regulora provides broad access to this treatment through a mechanism familiar to both patients and doctors: obtaining a prescription. By providing physicians an easy way to prescribe treatment and patients a convenient way to undergo therapy privately at home, Regulora offers a non-drug option that addresses the stigma often associated with bowel problems and psychological interventions.

metaMe Health is a pioneer in developing Prescription Digital Therapeutics (PDTs). In 2022, our work was recognized by being included on the “50 on Fire” list of up-and-coming Chicago companies, being named one of the Top 150 most promising Digital Health Companies of 2022 nationwide by CBInsights, and being selected as a finalist in the LyfeBulb-Bristol Myers Squibb Inflammatory Bowel Disease Challenge. In 2021, our lead product Regulora® became the first FDA-cleared PDT specifically for abdominal pain associated with irritable bowel syndrome (IBS) in adults. More than 30 million Americans are affected by IBS, and the abdominal pain, diarrhea, and/or constipation that comes with it. Regulora provides relief by digitizing a standardized Brain-Gut therapy approach that has been clinically proven to be effective in reducing IBS symptoms.

Perx Health is a digital care company building high-engagement digital care programs for high-risk chronic conditions patients. Our proprietary behavioral science delivers results for all types of patients regardless of their level of health literacy, socioeconomic status and/or complex co-morbidity. Perx is proven to improve clinical health outcomes in peer-reviewed research and generate 6x ROI of healthcare savings for our large enterprise customers.

Non-drug therapy with no side effects

Perx’s core value proposition is the ability to attract, engage and serve healthcare’s high-risk, highest-cost patient groups through our unique approach. Our completely customizable and modular solution can map into internal tools and has features and outcomes beyond any homegrown tool:

• Engaging Experience: a variety of extrinsic and intrinsic motivators (gamification, extrinsic rewards, community support and challenges) to engage individuals in a personalized way. Participants in our programs use Perx 3-4 times a day, with daily engagement (72% of monthly activity) equal to mobile consumer applications Facebook and Twitter (66% and 46% respectively).
• Comprehensive and configurable condition support: catering to all conditions and comorbidities with treatment plan management across medication schedules, exercise plans, appointment scheduling, measurement taking and health tasks. Our platform’s flexible modules can be configured to match the needs of our commercial partners.
• Clinically validated health outcomes: the University of Technology Sydney demonstrated in peer-reviewed research that Perx sustained long-term treatment adherence of 96% over six months, and in a randomized control trial with the University of Sydney, Perx patients demonstrated improved clinical bio-markers (HbA1c and cholesterol) versus standard care over 12 months.
• Real-time verified data capture: validation of treatment management in real-time using clinical trial standard methods such as mobile direct observation of therapy (mDOT), collection of patient-reported experience and outcome measures (PROMs), and any condition specific surveys to validate and improve health outcomes. These real-world evidence capabilities are built into the platform to track program adoption, veteran satisfaction and report relevant health outcomes.

Perx’s digital CDMPs are designed to attract, engage and serve healthcare’s high-risk, highest-cost patient groups with a flexible, single solution, personalizing the experience through systematic ‘precision’ behavioral change while integrating with clinical care. We offer high-risk patients a materially different value proposition than our competitors:

• Gamified treatment interventions focus on gamification only, inadvertently treating high-risk individuals as a homogeneous population. Perx uses a range of behavioral strategies to personalise the experience, drive higher engagement, and enroll a more diverse cohort of patients.
• Digital CDMPs aim to control primary risk factors (blood pressure, glucose control or cholesterol) by modifying key risk behaviors (smoking, weight management, exercise, alcohol consumption). Unsuitable for high-risk patients, these programs focus on treating single conditions, are reliant on education and health coaching, and operate independently from clinical care teams.
• Wellness solutions focus on disease prevention by providing general health, wellbeing and lifestyle interventions (exercise, nutrition, mental wellbeing and health check-ups). While attractive to health-conscious populations, these solutions fail to engage low socioeconomic, health illiterate patients managing complex comorbidities.
• Patient access solutions pursue the mass-market and focus on patient acquisition (regardless of condition or health-risk). Solutions are monetised by selling data or providing patient access for marketing purposes, with little-to-no independently published research demonstrating behaviour change or outcomes.